

ERRATUM

Erratum to ‘How we treat primary central nervous system lymphoma’



[ESMO Open Volume 6, Issue 4, August 2021, 100213]

T. Calimeri¹, S. Steffanoni¹, F. Gagliardi², A. Chiara³ & A. J. M. Ferreri^{1*}

¹Lymphoma Unit, Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan; ²Department of Neurosurgery and Gamma Knife Radiosurgery, San Raffaele Scientific Institute, Vita-Salute University, Milan; ³Department of Radiation Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy

The publisher regrets that at the time the article was published the wrong article type was used. This has now been corrected to include highlights, keywords and an abstract.

In addition, in Table 1, the word “vitreous-retina” has been replaced with “vitreoretinal” in the following sentence: To carry out cytological diagnosis on primary vitreoretinal lesion. In the section “How we treat patients with relapsed or refractory disease”, this same word replacement has been carried out in the following sentence: “Immunomodulatory drugs (lenalidomide and pomalidomide) have been investigated in patients with relapsed or refractory PCNSL or primary vitreoretinal lymphoma achieving an objective response in half of the patients, but the response was usually short lived.”

The publisher would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.esmoop.2021.100213>

*Correspondence to: A. J. M. Ferreri

E-mail: ferreri.andres@hsr.it (A. J. M. Ferreri).

2059-7029/© 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. All rights reserved.